Role of ongoing support for people with diabetes can improve glycaemic control with results seen comparable to treatment with expensive pharmacological agents Weight management groups can offer this support, and help obese people with diabetes manage their weight and glycaemic control Healthcare encouragement increases physical activity levels which may further enhance weight management and glycaemic control.
Introduction
Sustainable, scalable and cost effective approaches reducing chronic health risks associated with diabetes and obesity are required. Group education, emphasising self-management and maintenance of weight loss, is an accepted approach (NICE, 2015) . Currently most UK diabetes and weight management education is short-term with local variation but diabetes is a lifelong condition and people are likely to benefit from access to on-going support. There are few ongoing group based programmes for people with diabetes, which are scalable, with evidence of long-term effectiveness (Brown et al, 2015) .
Commercial group weight management programme (CGWMP) provider organisations are well placed to work in partnership with healthcare professionals to help people with diabetes lose weight and improve their glycaemic control. However, the effect of ongoing membership of a CGWMP on diabetes control has not previously been described.
This study evaluates the electronically reported weight changes in a subgroup of people with diabetes (both T1DM and T2DM) attending a CGWMP. The self-reported changes in glycaemic control (HbA1c) were compared against current clinical standards set by NICE (2015) . Changes in levels of physical activity and diabetes medication were investigated.
Materials and Methods
A combination of a cross-sectional online survey, posted on the members' only section of Slimming World's website between 21 st July and 9 th August 2013, and data collected through the CGWMP provider's electronic weight record system were linked and analysed. The survey consisted of questions exploring type of diabetes, duration of diabetes, and glycaemic control with reported HbA1c at the time of joining and current values. In addition demographics including age and gender were requested alongside self-reported changes in physical activity levels, information about changes in medications taken to improve glycaemic control and support received from healthcare professionals.
The survey was designed specifically for this study, with the intention of being easy to complete and in language with which the participants attending the programme were familiar.
The questionnaire was constructed and administered using Checkbox v4. 
Results
A total of 620 members responded to the questionnaire. Table 1 shows the baseline characteristics. Responding members had a median length of membership of 6.0 months at point of survey (Range 0-24 months; IQR 11.0 months; mean value12±9.8 months).
Respondents to the survey were 88% (n=546) female and 88% (n=547) reported having T2DM.
On joining the CGWMP, there were differences between genders and those with T1DM and T2DM ( Respondents who reported reducing their diabetes related medication reported a significantly greater reduction in HbA1c 24±22 mmol/mol (2.2±2.0%, n=83) compared to those who had not 13±18 mmol/mol (1.2±1.6%, n=73, p=0.001). When this was considered in terms of type of medication reduced there was no significant association with any type of medication (p=0.073). Respondents who reported reducing their diabetes medication lost a significantly greater percentage of their starting bodyweight, -10.9±7.2% (n=74) compared to -8.2±7.9%
(n=74) for those who did not decrease their medication (p=0.028). The type of medication reduced did not affect the amount of weight loss (p=0.0249).
Reported change in physical activity was examined as a potential confounding variable, with 72.3% (n=448) of respondents reporting an increase in physical activity. Members who reported an increase in physical activity did not lose significantly more weight (11.9±10.5kg
for those reporting increased physical activity compared with 8.5±8.2kg; p=0.094). Reporting an increase in physical activity was associated with being advised to lose weight by a healthcare professional (p<0.001), with those with T2DM being more likely to report an increase in physical activity than those with T1DM (p=0.001). Change in medication dose and decreases in insulin were not associated with an increase in physical activity (p=0.272). Reported increases in physical activity was not associated with an improved HbA1c (p=0. 654).
Duration of membership, significantly increased weight loss (p<0.001) if greater than 12 weeks, and the loss was maintained for at least one year, but the effect of duration of membership on HbA1c was not significant (p=0.126).
Discussion
Slimming World (SW) is the largest CGWMP in the UK, currently running 16,000 group sessions each week, reaching 800,000 members weekly. It is estimated that approximately 10% of this number may have diabetes. Groups are located in a variety of local community venues throughout the UK across a range of days and times, making the groups easily accessible. The group facilitators are supported by regularly updated resources and dietitians based at Head office.
The majority of respondents had T2DM and with a starting BMI of over 39kg/m 2 . This pragmatic evaluation, using an on-line survey, reports significant weight loss and improvements in glycaemic control, as measured by self-reported changes in HbA1c levels, in people with both T1 and T2DM attending the CGWMP. Reductions in weight and improved glycaemic control were associated with reduced need for diabetes medication. Although a selfselecting sample, with a current median membership of 6 months, this study provides evidence that long term management can improve the key markers of weight and HbA1c whilst reducing medication requirements. Although length of membership does not increase reductions in HbA1c, it supports the suggestion that improvements in glycaemic control are maintained. This is concordant with the findings of Trento and colleagues (2010) that diabetes is not necessarily, with good self-management, a progressive condition.
Currently in the UK only Orlistat is licensed for weight management and although caution needs to be taken in comparing this evaluation with a randomized controlled trial, 72.5% of respondents lost at least 5% of body weight at 12 weeks which increased to 81.3% at 24 weeks.
This compares to 51.3% at 1 year for Orlistat (compared to 31.6% for placebo) in a population with T2DM (Hanefield & Sachse, 2002) .
The respondents reported a mean decrease in HbA1c of 18mmol/mol (1.6%), which is comparable to the 22mmol/mol (2.0%) reported in the DCCT study (1993) for T1DM and almost double that reported in the UKPDS study (1998), associated with a 50% reduction in microvascular complications in T1DM 5 and 10% reduction in diabetes related deaths in There are few ongoing group NHS based programmes for obese people with diabetes, which are scalable, with evidence of long-term effectiveness. The data reported in this study can be compared with data from the subset of 142 patients with diabetes who completed the SLiM 6-month programme facilitated by trained dietetic assistants. The mean weight loss reported for the SLiM programme was 5.7±6.9kg (p=0.001) with 30% of patients with diabetes achieving ≥5% and 11% achieving ≥10% weight loss over the 6 months, with those who lost weight achieving a mean weight loss of 4.0±4.6%. A mean reduction in HbA1c of 4.0±14.8mmol/l was reported, representing a change from 64.0±18.2mmol/l at base-line to 60.1±15.5mmol/l at the end of the programme (Brown et al, 2015) .
Comparing data suggests that membership of weight management groups can provide valuable long term support for people with diabetes wishing to lose weight and improve their health. It should be recognized that improvements in health might not be entirely dependent on weight loss but might also be related to associated changes in dietary behaviours, not reported here, or increased physical activity levels. The group and peer support may also contribute to the weight loss maintenance reported and is an area requiring further exploration (MacLean et al, 2015) .
The findings may be of relevance to the quest to find scalable solutions to reduce HbA1c levels in people presenting with prediabetes. A CGBWMP offers a non-clinical support option, and as diabetes is a long-term condition requiring self-management, this in itself might explain some of its benefits and value. Diabetes UK (2015) 
Limitations
This cross sectional survey represents a fluid sample of around 1% of the total number of people with diabetes attending SW groups. All were still attending the groups having been members for variable lengths of time. Thus, the results may not reflect the overall impact of the intervention.
The use of self-reported retrospective information, apart from weight and attendance, is a potential limiting factor. The overall nature of self-reported studies of this type; means that the data may represent a self-selection bias, in that those who chose to participant may be those who achieve better outcomes in terms of weight and improvement in glycaemic control and therefore may be more likely to respond positively to survey requests. Although this is possible it is considered that online surveys are no more prone to this than paper based surveys (Weigold et al, 2013) . Therefore, a main limitation is the self-reported HbA1c which unlike the weight data could not be verified in this study, and should be an area of focus for future work.
Adverse event reporting, especially the incidence of hypoglycaemia related to changes in dietary patterns and doses of insulin and sulphonylureas was not reported within the scope of this study.
Although there are a number of methodological limitations to consider, the results suggest that attending a CGWMP is beneficial to people with diabetes. Although weight loss is known to improve HbA1c and reduce medication usage, it is also significant that these are not necessarily interdependent, and improved lifestyle behaviours associated with group attendance may explain the observations seen. This observation has been supported by other lifestyle interventions in groups with diabetes 3 and warrants further investigation.
Conclusion
People with both T1DM and T2DM, who attend a CGWMP can achieve clinically significant weight loss and glycaemic control as measured by changes in HbA1c levels. Improvements in physical activity levels and decreases in diabetes medication can also be achieved. The data supports the role of healthcare professionals encouraging the person with diabetes to lose weight, with these individuals apparently experiencing better glycaemic control, and this partnership approach warrants further emphasis and exploration. Whilst it is important for prospective research to fully assess the role of CGWMPs in supporting the self-management of people with diabetes. The mean length of attendance suggests that CGWMPs may offer long-term support to both long-term conditions (diabetes and obesity) and given the infrastructure of these organisations, this may offer a scalable solution to the associated public health burden. Figure 1: Percentage of survey respondents achieving the NICE target for HbA1c(<48mmol/l or <6.5%) . As data is cross-sectional, it is not possible to adjust for attendance; median attendance was 6 months. n=138 for respondents with T2DM and 39 for respondents with T1DM reporting a HbA1c at time of joining, and n=128 for respondents with T2DM and 33 for respondents with T1DM at the time of survey reported a HbA1c. 
